Valuation: Arrowhead Pharmaceuticals, Inc.

Market Cap 8.34B 7.48B 6.92B 6.26B 11.7B 794B 11.84B 82.7B 32.94B 416B 31.29B 30.63B 1,319B P/E 2026 *
-16.4x
P/E 2027 * -12.6x
Enterprise Value 7.51B 6.73B 6.23B 5.64B 10.53B 715B 10.66B 74.44B 29.65B 374B 28.17B 27.57B 1,188B EV / Sales 2026 *
16.2x
EV / Sales 2027 * 23.3x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Arrowhead Pharmaceuticals, Inc.

1 day-0.04%
1 week+0.02%
Current month-10.08%
1 month-10.10%
3 months-31.39%
6 months-16.08%
Current year-11.36%
1 week 56.56
Extreme 56.56
60.56
1 month 55.83
Extreme 55.83
66.83
Current year 54.02
Extreme 54.02
95.49
1 year 37.06
Extreme 37.06
95.49
3 years 9.57
Extreme 9.57
95.49
5 years 9.57
Extreme 9.57
95.49
10 years 1.2
Extreme 1.2
95.49
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2007
Director of Finance/CFO - 13/05/2025
Chief Tech/Sci/R&D Officer - 01/08/2022
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 19/08/2010
Director/Board Member 66 19/12/2011
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Sell

Director

-2,000 0.0014%
18/08/26 Sell

Director

-11,600 0.0082%
15/06/26 Free

Director

11,882 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
-0.03%+0.02%+48.80%+153.45% 8.34B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+1.81%-0.24%+26.52%+55.77% 44.75B
+2.11%-3.30%+17.95%+100.27% 41.62B
+0.34%-3.98%+220.70%+916.62% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +3.90%-0.36%+51.28%+160.78% 38.88B
Weighted average by Cap. +2.94%-0.28%+47.04%+160.14%

Financials

2026 *2027 *
Net sales 464M 416M 385M 349M 651M 44.21B 659M 4.6B 1.83B 23.13B 1.74B 1.7B 73.43B 328M 294M 272M 247M 461M 31.26B 466M 3.26B 1.3B 16.36B 1.23B 1.21B 51.93B
Net income -513M -460M -425M -385M -719M -48.82B -728M -5.08B -2.02B -25.55B -1.92B -1.88B -81.1B -663M -595M -550M -498M -931M -63.17B -942M -6.58B -2.62B -33.05B -2.49B -2.44B -105B
Net Debt -832M -747M -690M -625M -1.17B -79.27B -1.18B -8.26B -3.29B -41.48B -3.12B -3.06B -132B -683M -613M -566M -513M -958M -65.03B -970M -6.77B -2.7B -34.03B -2.56B -2.51B -108B
Projected Income Statement - Annual - Arrowhead Pharmaceuticals, Inc.
Logo Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
711
Date Price Change Volume
28/10/26 $59.09 +0.10% 585,297
27/10/26 $59.03 +0.08% 2,118,861
26/10/26 $58.98 +1.65% 979,892
23/10/26 $58.02 -0.58% 871,820
22/10/26 $58.36 -0.82% 1,036,553
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Arrowhead Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
59.03USD
Average target price
107.71USD
Spread / Average Target
+82.47%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arrowhead Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARWR Stock